TP53 and acute myeloid leukemia: In TP53 mutant blasts with true loss of the second TP53 allele (deletion or cnLOH), there is no mutant protein to “refold,” which would imply that eprenetapopt’s p53-reactivation mechanism is intrinsically ineffective for biallelic or multi-hit TP53 mutant AML patients.